Meet the newest Master of the Industry. Jim Mazzo, who has led divisions, spin-outs, and start-ups, now leads what looks to be a new leader in ophthalmology. Hear how Mazzo views this new opportunity for Zeiss and himself.

Over two decades ago, Mark Humayun – who will co-chair our upcoming OIS@ASRS meeting in San Francisco – helped launch a “moonshot” that would eventually restore vision for retinitis pigmentosa patients. In this podcast we discuss what drives him and what’s next for ophthalmology.

Cartiva secured an historic win when the FDA approved its synthetic cartilage. CEO Tim Patrick explains what it took to get the approval and how the company will sell going forward.

Eric Timko, the former CEO of Blue Belt, shares how the company used MAKO’s wake to build a market for its surgical robot and sell the business to Smith & Nephew. Timko explains the company’s fast-follower strategy and shares what he’s looking to do next.

The board at Ulthera, an aesthetics device company, faced an attractive dilemma. Take the company public? Or accept a lucrative buyout? Hear from the CEO how the company’s culture and approach led to that favorable outcome.

Gilde Healthcare Partner Geoff Pardo shares how the firm will invest its new $250 million in health care companies, including Medtech.

Julie Allen, principal of Allen Partners, shares insights on how Medtech executives must work to find the right fit and how companies can build their best team.

The experienced CEOs on this panel have authored some of the greatest stories in Medtech. In this discussion, they delve into their approaches to managing start-ups to multi-million – or billion – dollar acquisitions or IPOs. How do they accurately assess a struggling company and direct a team to turn weakness into strength?

Medtronic executive VP Geoff Martha talks with OISTV about how the Medtech giant views robotics, payers, and where health care transformation is the most difficult. The podcast also includes a clip from his keynote interview at the Medtech Conference.

For years, Intuitive Surgical appeared to be the only company capable of cracking the code for medical robotics. But with companies like Medtronic, Stryker, Johnson & Johnson, Google, and others creating their own efforts the sector appears to be stabilizing. Is there room for early-stage entrepreneurs and VC investors in this capital-intensive sector?